FORA Capital LLC bought a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 9,619 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,408,000. Other hedge funds and […]
Baupost Group LLC MA acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 478,696 shares of the specialty pharmaceutical company’s stock, valued at approximately $70,048,000. Jazz Pharmaceuticals makes up […]
Profund Advisors LLC reduced its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 7.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,475 shares of the specialty pharmaceutical company’s stock after selling 532 shares during the quarter. Profund […]
Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have been assigned an average recommendation of “Buy” from the six research firms that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the […]
Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221 Q2 2023 YUPELRI total retail TRx and new to product TRx.